JPWO2020249977A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249977A5 JPWO2020249977A5 JP2021571931A JP2021571931A JPWO2020249977A5 JP WO2020249977 A5 JPWO2020249977 A5 JP WO2020249977A5 JP 2021571931 A JP2021571931 A JP 2021571931A JP 2021571931 A JP2021571931 A JP 2021571931A JP WO2020249977 A5 JPWO2020249977 A5 JP WO2020249977A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- dose
- demand
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 206010019860 Hereditary angioedema Diseases 0.000 claims 19
- 230000001154 acute effect Effects 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 230000008961 swelling Effects 0.000 claims 3
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 2
- 102100034869 Plasma kallikrein Human genes 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010013952 Dysphonia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000010473 Hoarseness Diseases 0.000 claims 1
- 206010027951 Mood swings Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000035824 paresthesia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131860A JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
| JP2025084646A JP2025124716A (ja) | 2019-06-14 | 2025-05-21 | 遺伝性血管性浮腫の治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861725P | 2019-06-14 | 2019-06-14 | |
| US62/861,725 | 2019-06-14 | ||
| GB1910116.1 | 2019-07-15 | ||
| GBGB1910116.1A GB201910116D0 (en) | 2019-07-15 | 2019-07-15 | Treatments of hereditary angioedema |
| PCT/GB2020/051439 WO2020249977A1 (en) | 2019-06-14 | 2020-06-15 | Treatments of hereditary angioedema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131860A Division JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536287A JP2022536287A (ja) | 2022-08-15 |
| JP2022536287A5 JP2022536287A5 (https=) | 2023-01-23 |
| JPWO2020249977A5 true JPWO2020249977A5 (https=) | 2023-01-23 |
| JP7356518B2 JP7356518B2 (ja) | 2023-10-04 |
Family
ID=67700145
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571931A Active JP7356518B2 (ja) | 2019-06-14 | 2020-06-15 | 遺伝性血管性浮腫の治療 |
| JP2023131860A Active JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
| JP2025084646A Pending JP2025124716A (ja) | 2019-06-14 | 2025-05-21 | 遺伝性血管性浮腫の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131860A Active JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
| JP2025084646A Pending JP2025124716A (ja) | 2019-06-14 | 2025-05-21 | 遺伝性血管性浮腫の治療 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20220218680A1 (https=) |
| EP (2) | EP4282474A3 (https=) |
| JP (3) | JP7356518B2 (https=) |
| KR (1) | KR102748728B1 (https=) |
| CN (1) | CN114126612A (https=) |
| AR (1) | AR119158A1 (https=) |
| AU (1) | AU2020293614B2 (https=) |
| BR (1) | BR112021024664A2 (https=) |
| CA (1) | CA3142218A1 (https=) |
| CL (2) | CL2021003244A1 (https=) |
| DK (1) | DK3982960T3 (https=) |
| EA (1) | EA202193019A1 (https=) |
| ES (1) | ES2956471T3 (https=) |
| FI (1) | FI3982960T3 (https=) |
| GB (1) | GB201910116D0 (https=) |
| HR (1) | HRP20230696T1 (https=) |
| HU (1) | HUE063163T2 (https=) |
| IL (1) | IL288615A (https=) |
| LT (1) | LT3982960T (https=) |
| MA (1) | MA56187B1 (https=) |
| MD (1) | MD3982960T2 (https=) |
| MX (1) | MX2021014557A (https=) |
| MY (1) | MY205687A (https=) |
| PH (1) | PH12021552966A1 (https=) |
| PL (1) | PL3982960T3 (https=) |
| PT (1) | PT3982960T (https=) |
| RS (1) | RS64412B1 (https=) |
| SG (1) | SG11202113304YA (https=) |
| SI (1) | SI3982960T1 (https=) |
| SM (1) | SMT202300261T1 (https=) |
| TW (1) | TW202112370A (https=) |
| UA (1) | UA129869C2 (https=) |
| WO (1) | WO2020249977A1 (https=) |
| ZA (1) | ZA202110685B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| US20230381162A1 (en) * | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) * | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| US20250281397A1 (en) | 2022-04-27 | 2025-09-11 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2026003532A1 (en) | 2024-06-28 | 2026-01-02 | Kalvista Pharmaceuticals Limited | Sebetralstat for the treatment of anxiety associated with hereditary angioedema |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| EP2590945B1 (en) | 2010-07-07 | 2014-04-30 | The Medicines Company (Leipzig) GmbH | Serine protease inhibitors |
| US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| MY174018A (en) | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
-
2019
- 2019-07-15 GB GBGB1910116.1A patent/GB201910116D0/en not_active Ceased
-
2020
- 2020-06-15 EP EP23181261.1A patent/EP4282474A3/en active Pending
- 2020-06-15 SM SM20230261T patent/SMT202300261T1/it unknown
- 2020-06-15 KR KR1020217043374A patent/KR102748728B1/ko active Active
- 2020-06-15 BR BR112021024664A patent/BR112021024664A2/pt not_active Application Discontinuation
- 2020-06-15 FI FIEP20734283.3T patent/FI3982960T3/fi active
- 2020-06-15 PH PH1/2021/552966A patent/PH12021552966A1/en unknown
- 2020-06-15 TW TW109120108A patent/TW202112370A/zh unknown
- 2020-06-15 MX MX2021014557A patent/MX2021014557A/es unknown
- 2020-06-15 CN CN202080043365.6A patent/CN114126612A/zh active Pending
- 2020-06-15 EP EP20734283.3A patent/EP3982960B1/en active Active
- 2020-06-15 UA UAA202106869A patent/UA129869C2/uk unknown
- 2020-06-15 ES ES20734283T patent/ES2956471T3/es active Active
- 2020-06-15 HU HUE20734283A patent/HUE063163T2/hu unknown
- 2020-06-15 US US17/617,439 patent/US20220218680A1/en active Pending
- 2020-06-15 MA MA56187A patent/MA56187B1/fr unknown
- 2020-06-15 SG SG11202113304YA patent/SG11202113304YA/en unknown
- 2020-06-15 LT LTEPPCT/GB2020/051439T patent/LT3982960T/lt unknown
- 2020-06-15 MD MDE20220440T patent/MD3982960T2/ro unknown
- 2020-06-15 CA CA3142218A patent/CA3142218A1/en active Pending
- 2020-06-15 JP JP2021571931A patent/JP7356518B2/ja active Active
- 2020-06-15 WO PCT/GB2020/051439 patent/WO2020249977A1/en not_active Ceased
- 2020-06-15 SI SI202030247T patent/SI3982960T1/sl unknown
- 2020-06-15 DK DK20734283.3T patent/DK3982960T3/da active
- 2020-06-15 PT PT207342833T patent/PT3982960T/pt unknown
- 2020-06-15 EA EA202193019A patent/EA202193019A1/ru unknown
- 2020-06-15 RS RS20230620A patent/RS64412B1/sr unknown
- 2020-06-15 HR HRP20230696TT patent/HRP20230696T1/hr unknown
- 2020-06-15 MY MYPI2021007320A patent/MY205687A/en unknown
- 2020-06-15 PL PL20734283.3T patent/PL3982960T3/pl unknown
- 2020-06-15 AU AU2020293614A patent/AU2020293614B2/en active Active
- 2020-06-16 AR ARP200101681A patent/AR119158A1/es unknown
-
2021
- 2021-12-02 IL IL288615A patent/IL288615A/en unknown
- 2021-12-06 CL CL2021003244A patent/CL2021003244A1/es unknown
- 2021-12-20 ZA ZA2021/10685A patent/ZA202110685B/en unknown
-
2023
- 2023-03-06 CL CL2023000639A patent/CL2023000639A1/es unknown
- 2023-08-14 JP JP2023131860A patent/JP7688078B2/ja active Active
-
2025
- 2025-05-21 JP JP2025084646A patent/JP2025124716A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3982960T3 (fi) | Perinnöllisen angioödeeman hoitoja | |
| CA2683779C (en) | Tapentadol for treating pain due to osteoarthritis | |
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| JPWO2020249977A5 (https=) | ||
| JP2002524498A (ja) | 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用 | |
| CA3107624C (en) | Composition for eradicating helicobacter pylori | |
| JPH0920659A (ja) | 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬 | |
| TW202545526A (zh) | 低劑量三重組合調配物 | |
| CN1744897A (zh) | 结合有泰妥拉唑与消炎剂的药物组合物 | |
| EP1704860B1 (en) | Benzamidine derivatives for treatment and prevention of mucositis | |
| JPWO2020249979A5 (https=) | ||
| AU2011283462B9 (en) | Therapeutic agent or prophylactic agent for neuropathic pain | |
| IE851848L (en) | Propiophenone compound against sexual dysfunction | |
| NZ782935B2 (en) | Treatments of hereditary angioedema | |
| CN1893942A (zh) | 加波沙朵治疗失眠症的用途 | |
| CN1744896B (zh) | 结合有泰妥拉唑和组胺h2受体拮抗剂的药物组合物 | |
| AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN1263465A (zh) | 利用选择性5－羟色胺再摄取抑制剂治疗和预防心脏病 | |
| AU2006226381B2 (en) | Use of macrolides for treating intestinal inflammation | |
| US7470690B2 (en) | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder | |
| CA2612179A1 (en) | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion | |
| CN115279354B (zh) | 氯胺酮用于治疗恶病质的用途 | |
| CN111035763A (zh) | 一种治疗妇女更年期综合症的药物组合物 | |
| KR20090130058A (ko) | 두개골 외상의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도 | |
| CN115998735A (zh) | 一种伏乌碱在制备镇痛药物中的应用 |